New York-based Definium Therapeutics (Nasdaq: DFTX) reported positive topline results from the Emerge Phase III trial of DT120 (lysergide) orally disintegrating tablet in major depressive disorder, positioning a pharmaceutically optimized formulation of LSD as a potential single-dose treatment for one of psychiatry's most treatment-resistant conditions. The result matters because it is the first Phase III readout for a classic psychedelic in MDD, and it arrives at a moment when the field is actively debating whether the functional unblinding inherent to psychedelic trials can produce credible, interpretable efficacy data.
The primary endpoint — change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 — showed a placebo-adjusted least squares mean reduction of 8.1 points (p<0.0001), with active treatment producing a MADRS change of −13.3 versus −5.2 for placebo. Response rates at Week 6 were 35% versus 7%, and remission rates 24% versus 3%, both statistically significant. Notably, the effect emerged rapidly: a placebo-adjusted MADRS reduction of 14.2 points was observed at Week 1 (p<0.0001), and a CGI-S improvement of 0.9 points was recorded by Day 2. The effect also showed durability, with a placebo-adjusted MADRS reduction of 7.3 points maintained at Week 12 (p<0.0001) — all from a single dose administered under clinical supervision.
The trial enrolled 149 adults with DSM-5-confirmed MDD and a baseline MADRS score of at least 26, across 20 sites. Safety was generally favorable: 99% of treatment-emergent adverse events were mild to moderate, transient, and concentrated on the day of dosing. No serious adverse events were reported, and there was no suicidality signal.
Competitive context
The 8.1-point placebo-adjusted MADRS improvement sits meaningfully above the approximately 3-point threshold historically considered clinically relevant, and above the typical 2–4 point placebo-adjusted effect seen with conventional antidepressants in acute trials. Cross-trial comparisons are limited, but the magnitude and speed of effect — combined with a single-dose administration — distinguish DT120 from both standard-of-care SSRIs and SNRIs, which require weeks of daily dosing, and from Johnson & Johnson's Spravato (esketamine), an intranasal NMDA antagonist approved for treatment-resistant depression that requires repeated supervised sessions. The closest psychedelic competitor is Australia-based Awakn Life Sciences and, more prominently, MAPS-affiliated programs exploring MDMA-assisted therapy for PTSD, which target a different indication. In MDD specifically, no psychedelic compound has previously reached Phase III, making Definium's data the first of their kind in the field.